Figure 12 — Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma

Navigate

Research Paper|Volume 13, Issue 14|pp. 18701–18717

Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma

Back to articleFigure 12(12 of 13)

100%

Figure 12.Kaplan–Meier survival analysis is performed on the hub genes. (A) ARRB1, (B) PARP1, (C) PKM, (D) TFDP1, (E) YWHAZ.

Figure 12 — Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma | Aging